Parkinson’s Disease
-
Bayer Pushes Ahead With Parkinson’s Cell Therapy on Heels of Positive Phase 1 Data
A Bayer cell therapy for Parkinson’s disease has met primary and secondary goals of its first test in humans, and the pharmaceutical giant is now planning for a larger Phase 2 clinical trial expected to begin enrollment in the first half of next year.
-
Cala Health Launches Wearable Device to Treat Hand Tremors
Cala Health recently launched its kIQ system — which it calls the first noninvasive wearable device cleared by the FDA to temporarily relieve tremors in people with essential tremor and Parkinson’s disease.
-
Payer’s Place: Dr. Anil Singh
Dr. Anil Singh shares his insights into the strategies employed by the organization to identify the most effective digital solutions for their members.
-
Parkinson’s Trial Failure Signals a Likely End for CNS Biotech Aptinyx
An Aptinyx Parkinson’s disease drug candidate failed to beat a placebo—the biotech’s third mid-stage failure in the past year. Aptinyx is now terminating a separate PTSD program, cutting costs, and exploring “strategic alternatives.”
-
Neurocrine Commits $175M to Voyager in New Neuro Gene Therapy Alliance
Neurocrine Biosciences is paying $175 million up front for rights to a preclinical Voyager Therapeutics gene therapy that could put the biotech in competition with Eli Lilly among other companies. Voyager could earn up to $4.2 billion in milestone payments.
-
Devices & Diagnostics, BioPharma, Health Tech
Neuro startups form latest group of grads from PharmStars digital health accelerator
PharmStars, a digital health accelerator, graduated its latest cohort of startups, each of them developing a solution addressing some aspect of neurological disease. The accelerator is accepting applications for the next group of startups for the fall program. The theme is innovations in real-world evidence.
-
Aiming to treat Parkinson’s by replacing neurons, Aspen Neuroscience nabs $147M
Aspen Neurosciences is developing a cell therapy that uses a patient’s own stem cells to develop a personalized treatment for Parkinson’s disease. The approach is slightly different than that of Bayer, whose experimental Parkinson’s cell therapy is made from stem cells sourced from healthy donors.
-
MedCity Influencers, Health Tech
Without brain data, we won’t improve outcomes for patients who have neurological diseases
New technologies for quantifying behavioral information and tracking neurological patterns have the potential to change treatment—but we must connect the data.
-
Vying to best bigger rivals in Parkinson’s, Neuron23 nabs $100M to reach clinic
Neuron23 is developing drugs that treat neurological conditions by penetrating the blood-brain barrier to reach disease targets in the central nervous system. The biotech’s lead program is a Parkinson’s disease drug candidate with features that could distinguish it from rival compounds that are aiming for the same target.
-
Cash woes at neuro biotech Yumanity lead to 60% staff cut and search for a buyer
Yumanity’s corporate restructuring means the biotech is now exploring “strategic alternatives” that could include a sale of the company or its assets. The biotech’s lead drug candidate is an experimental Parkinson’s disease drug currently in Phase 1 testing.
-
Discover the Next-Gen Platform for Integrated Collaborative Care
Beyond EHRs and digital front doors, reducing the gaps in patient care journeys.
-
Sanofi shores up neuro pipeline with deal for brain-penetrating Parkinson’s drug
Sanofi is the latest company to strike a deal for a Parkinson’s disease drug candidate that targets the protein alpha synuclein. The asset from ABL Bio is a bispecific antibody designed to penetrate the blood-brain barrier.
-
Novartis boosts neuro pipeline through alliance on UCB Parkinson’s drugs
Novartis is paying UCB $150 million up front to share in the development of two clinical-stage Parkinson’s disease drugs that offer new approaches to treating the disease. Depending on the progress of those drugs, UCB could earn up to $1.5 billion in milestone payments.
-
At HLTH, a case for empowering patients in research
At HLTH, leaders of the Michael J. Fox Foundation shared the importance of including patient voices in research, and how engaging patients has led to important findings in Parkinson’s research.
-
Neuro startup Vanqua Bio emerges with $85M and a first focus on Parkinson’s
Vanqua Bio aims to treat rare form of Parkinson’s disease by boosting activity of an enzyme that is deficient in patients who have a particular genetic mutation. With $85 million in Series B financing, the biotech startup, which is based on Northwestern University research, aims to reach human testing within two years.
-
Health IT, Hospitals, Artificial Intelligence
Mayo Clinic, Google develop AI algorithm to enhance electrical brain stimulation
The algorithm maps interactions between different areas of the brain, which can help guide the placement of electrodes for stimulating devices to treat brain diseases, like epilepsy, and movement disorders.
-
AC Immune picks up Phase 2-ready drug for Parkinson’s in $58M deal with Affiris
AC Immune is bolstering the Parkinson’s disease portion of its drug pipeline with a deal to acquire a therapeutic vaccine that Affiris is developing for the disorder. Switzerland-based AC Immune plans to advance its new asset to Phase 2 testing.